There are currently 1022 clinical trials in Aurora, Colorado looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Hospital Colorado, University of Colorado, University of Colorado Hospital and University of Colorado - Denver. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Observational Study of THC Concentrations in Acute Cannabinoid Intoxication
NCT06017622
Recruiting
This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of subjects who visit the emergency department due to acute cannabinoid intoxication.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2024
Locations: University of Colorado School of Medicine, Aurora, Colorado
Conditions: Acute Cannabinoid Intoxication
Register for Updates
A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules
NCT06074133
Recruiting
This is a prospective, multicenter observational study aim at estimating the potential clinical utility of the CBM and at establishing the SOPs and protocols for a future randomized control trial.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/26/2024
Locations: Rocky Mountain Regional VA Medical Center, Aurora, Colorado +1 locations
Conditions: Pulmonary Nodule
Register for Updates
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Kaiser Foundation Research Institute, a Division of Kaiser Permanente Hospitals, Aurora, Colorado
Conditions: Ulcerative Colitis
Register for Updates
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2024
Locations: Sensation-NOW: University of Colorado School of Medicine, Aurora, Colorado
Conditions: Peripheral Nerve Injuries
Register for Updates
Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation
NCT06518746
Recruiting
The "Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation" study is open to a subset of patients with disorders of sex development (DSD) which is associated with the risk of malignancy and a high risk of infertility or sterility. For these patients, experimental gonadal tissue cryopreservation is the only fertility preservation option available. The overall objective of this study is to determine the safety and efficacy of gonadal tissue cryopreservation as a method of preservin... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
07/18/2024
Locations: University of Colorado, Aurora, Colorado
Conditions: Ovarian Cancer
Register for Updates
Pediatric Medication Therapy Management Trial
NCT05761847
Recruiting
The purpose of this study is to evaluate whether an intervention called Pediatric Medication Therapy Management (pMTM) improves the identification and management of medication-related problems among children with medical complexity and polypharmacy.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
07/12/2024
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Child, Only, Disabilities Multiple, Medication Interaction, Medication Compliance, Medication Administered in Error
Register for Updates
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
NCT05785819
Recruiting
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2024
Locations: University of Colorado, Aurora, Colorado
Conditions: Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Register for Updates
Early Intervention to Promote Cardiovascular Health of Mothers and Children
NCT06272045
Recruiting
Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) is a cluster randomized clinical trial, funded by the National Heart Lung \& Blood Institute. The study is designed to test the effectiveness of home visiting intervention to promote cardiovascular health and reduce disparities in maternal and early childhood cardiovascular health. Sites, in partnership with evidence-based home visiting programs, are recruiting 6400 participants in total (i.e., 3200 parent-dyads... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2024
Locations: University of Colorado, Aurora, Colorado
Conditions: Cardiovascular Health
Register for Updates
Sinus Disease in Young Children With Cystic Fibrosis
NCT06191640
Recruiting
This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Out... Read More
Gender:
ALL
Ages:
Between 2 years and 8 years
Trial Updated:
07/08/2024
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder, Olfactory Impairment
Register for Updates
Shingrix in Renal Transplant Recipients
NCT04128189
Recruiting
This study evaluates the safety and immune response of the Shingrix vaccine in kidney transplant recipients. Participants on the waiting list for kidney transplant will be given the standard 2 doses of Shingrix. Those participants who have been transplanted by 16 months, may be given a 3rd dose of Shingrix.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/03/2024
Locations: University of Colorado Anschutz, Aurora, Colorado
Conditions: Kidney Transplant Recipient Response to Shingrix Vaccine
Register for Updates
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
NCT06496542
Recruiting
The proposed research is a pilot study assessing kidney oxidative metabolism and insulin sensitivity after a 2-year weight loss intervention in those with autosomal dominant polycystic kidney disease who are overweight or obese.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/03/2024
Locations: University of Colorado- Anschutz Medical Campus, Aurora, Colorado
Conditions: Autosomal Dominant Polycystic Kidney
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado +3 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates